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Therapy in Primary Percutaneous Coronary
InterventionWe thank Lozano et al. for their thoughtful comments
on our ETAMI (Early Thienopyridine Treatment to
Improve Primary PCI in Patients With Acute Myocar-
dial Infarction) trial (1) and fully agree with their
statement that in antithrombotic therapy, there
should always be a balance between efﬁcacy and
safety. Our study has investigated the very acute
phase of primary percutaneous coronary intervention
(PCI) in ST-segment elevation myocardial infarction
(STEMI) in which a faster onset of action of a platelet
inhibition effect is desirable to reduce ischemic com-
plications of the procedure. In the recently published
ATLANTIC (A 30 Day Study to Evaluate Efﬁcacy and
Safety of Pre-hospital vs. In-hospital Initiation of
Ticagrelor Therapy in STEMI Patients Planned for
Percutaneous Coronary Intervention) trial, a very
early initiation of ticagrelor in the pre-hospital phase
leading to clinical relevant difference in platelet in-
hibition 1 h after PCI was associated with a reduction
in stent thrombosis compared with the same loading
dose started on average 31 min later in the hospital (2).
In addition, there are several reports linking inade-
quate platelet inhibition at the time of PCI to ischemic
complications, underscoring the importance of an
effective platelet periprocedural inhibition during
primary PCI (3). In the TRITON (Trial to Assess
Improvement in Therapeutic Outcomes by Optimizing
Platelet Inhibition With Prasugrel) trial, patients with
STEMI have especially beneﬁted from prasugrel
compared with clopidogrel without an increase
in bleeding complications (4). These results were
conﬁrmed by recent reports from real-life experience
of registries. Bleeding complications in TRITON
accumulated over time but were not statistically
different between clopidogrel and prasugrel in the
primary PCI group at 30 days as well as at 15 months
(4). The net clinical beneﬁt was clearly in favor of
prasugrel. The statement about a differential effect of
prasugrel between secondary and primary PCI in
STEMI is not correct, and this reference indicated no
statistical heterogeneity between the 2 groups (4).
This has been now well evaluated, and there is no
signiﬁcant interaction for the primary and secondary
endpoints and a consistent effect of prasugrel acrossall types of PCI performed in STEMI patients (5). The
numerical differences are related to the difﬁculties in
measuring periprocedural MI in primary PCI versus
secondary PCI and not related to the efﬁcacy of
prasugrel (5). The statement about contraindications
against prasugrel majorly relates to patients with prior
stroke, which is present in up to 3% of STEMI patients.
Elderly or patients with low body weight <60 kg might
be treated with the same loading dose of 60 mg and a
lower maintenance dose of 5 mg to reduce bleeding
complications.*Uwe Zeymer, MD
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Therapy Following
Anterior ST-Segment
Elevation Myocardial
InfarctionWe would like to commend LeMay et al. (1) for their
work addressing the important clinical conundrum
of whether to provide triple antithrombotic therapy
(TATT) for patients presenting apical akinesis/
